Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald SadoffGlenda E GrayAn VandeboschVicky CárdenasGeorgi ShukarevBeatriz GrinsztejnPaul A GoepfertCarla TruyersHein FennemaBart SpiessensKim OffergeldGert ScheperKimberly L TaylorMerlin L RobbJohn TreanorDan H BarouchJeffrey StoddardMartin F RyserMary A MarovichKathleen M NeuzilLawrence CoreyNancy CauwenberghsTamzin TannerKarin HardtJavier Ruiz-GuiñazúMathieu Le GarsHanneke SchuitemakerJohan Van HoofFrank StruyfMacaya Douoguihnull nullPublished in: The New England journal of medicine (2021)
A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe-critical disease, including hospitalization and death. Safety appeared to be similar to that in other phase 3 trials of Covid-19 vaccines. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.).